Application of the sG8 Scale in Real-World Geriatric Oncology Patients

Обзор

This study is a multicenter, prospective, observational study. The study included patients aged 65 and older with solid tumors requiring systemic anti-tumor therapy. All patients underwent screening using the sG8 scale before the start of treatment, followed by routine treatment based on a plan developed through clinician decision-making. The study did not intervene in any way with the patients' diagnosis and treatment, and relevant clinical data during the treatment process were recorded accurately for follow-up patients. Study data were obtained from the electronic medical record databases and hospital information systems of multiple centers, including Sichuan Cancer Hospital. Patient clinicopathological features, pathological diagnoses, clinical stages, previous treatment histories, as well as anti-tumor treatment regimens after patient enrollment, drug dosages per cycle, treatment start times, incidence and grades of adverse events (AEs), and tumor response were extracted and collected from the medical records. All data were entered, managed, quality-controlled, exported, and analyzed through a real-world data management platform (RWDMP).

Вмешательства

• Другое Geriatric Screening using the sG8 scale
  Geriatric screening using the sG8 scale

Первичные конечные точки

• The incidence of unplanned treatment delays and treatment interruptions [Срок оценки: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months]

Вторичные конечные точки (3)

• TRAE [Срок оценки: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months]
• ORR [Срок оценки: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months]
• PFS [Срок оценки: From date receiving anti-tumor therapy after the first screening assessment until date of disease progression or death or the end of study, whichever came first, assessed up to 12 months.]

Критерии участия

Критерии включения

• Patients aged 65 years or older.
• Patients with confirmed malignant tumors based on definitive pathological data.
• Patients who are assessed by clinicians to have indications for systemic anti-tumor therapy.
• Patients with a survival time greater than 12 weeks.

Критерии исключения

• Patients who do not meet the above inclusion criteria or are considered unsuitable for this study by the investigator due to other circumstances.
• Patients who are unwilling to cooperate in completing the sG8 scale assessment.
• Patients who do not understand the content of this study or are unwilling to participate.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT06939764 · EK2025-SG8

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗